Center/Research Area Affiliations
Through the study and development of technologies that overcome current translational hurdles, Dr. Vandenberghe is helping to position gene therapy as a broadly applicable clinical modality in ophthalmology. Previously, he developed a novel adeno-associated viral vector (AAV) platform, and in translational studies, he characterized those for safety and efficacy parameters in large animal models. His current research focuses on gene therapy for neurosensory disorders, especially retinal blindness. He is on the editorial board of Molecular Therapy and is an active member of the American Society of Cell and Gene Therapy, for which he chairs the educational committee. In addition, he co-founded GenSight Biologics, a biotech entity that pursues innovative ocular gene therapy strategies.
For more information please download his CV [PDF].
MS.c., Ph.D., Biological Engineering in Cellular and Genetic Biotechnology, Katholieke Universiteit Leuven, Belgium (2008)
Postdoctoral fellowship (James M. Wilson, MD PhD), Perelman School of Medicine, University of Pennsylvania (2007-2010)
Postdoctoral fellowship (Jean Bennett, MD PhD), Perelman School of Medicine, University of Pennsylvania (2010-2012)
2016: RPB Nelson Trust Awardee for Retinitis Pigmentosa
2017: Ed Gollob Board of Directors' Award, Foundation Fighting Blindness
2018: Outstanding New Investigator Award, American Society of Gene and Cell Therapy